{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:18:00Z","timestamp":1791919080879,"version":"4.3.4"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-14-CE13-0035"],"award-info":[{"award-number":["ANR-14-CE13-0035"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s13023-016-0405-3","type":"journal-article","created":{"date-parts":[[2016,3,18]],"date-time":"2016-03-18T20:53:17Z","timestamp":1458334397000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["The P42 peptide and Peptide-based therapies for Huntington\u2019s disease"],"prefix":"10.1186","volume":"11","author":[{"given":"Cecilia","family":"Marelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Maschat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,3,17]]},"reference":[{"key":"405_CR1","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S0140-6736(07)60111-1","volume":"369","author":"FO Walker","year":"2007","unstructured":"Walker FO. Huntington\u2019s disease. Lancet. 2007;369:218\u201328.","journal-title":"Lancet"},{"key":"405_CR2","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1750-1172-5-40","volume":"5","author":"RAC Roos","year":"2010","unstructured":"Roos RAC. Huntington\u2019s disease: a clinical review. Orphanet J Rare Dis. 2010;5:40.","journal-title":"Orphanet J Rare Dis"},{"key":"405_CR3","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1136\/jnnp-2012-304636","volume":"84","author":"SJW Evans","year":"2013","unstructured":"Evans SJW, Douglas I, Rawlins MD, Wexler NS, Tabrizi SJ, Smeeth L. Prevalence of adult Huntington\u2019s disease in the UK based on diagnoses recorded in general practice records. J Neurol Neurosurg Psychiatry. 2013;84:1156\u201360.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"405_CR4","doi-asserted-by":"crossref","unstructured":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes. The Huntington\u2019s Disease Collaborative Research Group. Cell 1993, 72:971\u2013983","DOI":"10.1016\/0092-8674(93)90585-E"},{"key":"405_CR5","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/00005072-198511000-00003","volume":"44","author":"JP Vonsattel","year":"1985","unstructured":"Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson Jr EP. Neuropathological classification of Huntington\u2019s disease. J Neuropathol Exp Neurol. 1985;44:559\u201377.","journal-title":"J Neuropathol Exp Neurol"},{"key":"405_CR6","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1126\/science.277.5334.1990","volume":"277","author":"M DiFiglia","year":"1997","unstructured":"DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, Vonsattel JP, Aronin N. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science. 1997;277:1990\u20133.","journal-title":"Science"},{"key":"405_CR7","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/00005072-199805000-00001","volume":"57","author":"JP Vonsattel","year":"1998","unstructured":"Vonsattel JP, DiFiglia M. Huntington disease. J Neuropathol Exp Neurol. 1998;57:369\u201384.","journal-title":"J Neuropathol Exp Neurol"},{"key":"405_CR8","volume":"3","author":"T Mestre","year":"2009","unstructured":"Mestre T, Ferreira J, Coelho MM, Rosa M, Sampaio C. Therapeutic interventions for symptomatic treatment in Huntington\u2019s disease. Cochrane Database Syst Rev. 2009;3:CD006456.","journal-title":"Cochrane Database Syst Rev"},{"key":"405_CR9","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.parkreldis.2011.10.021","volume":"18","author":"TA Mestre","year":"2012","unstructured":"Mestre TA, Ferreira JJ. An evidence-based approach in the treatment of Huntington\u2019s disease. Parkinsonism Relat Disord. 2012;18:316\u201320.","journal-title":"Parkinsonism Relat Disord"},{"key":"405_CR10","first-page":"RRN1260","volume":"3","author":"J-M Burgunder","year":"2011","unstructured":"Burgunder J-M, Guttman M, Perlman S, Goodman N, van Kammen DP, Goodman L. An International Survey-based Algorithm for the Pharmacologic Treatment of Chorea in Huntington\u2019s Disease. PLoS Curr. 2011;3:RRN1260.","journal-title":"PLoS Curr"},{"key":"405_CR11","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/mds.23953","volume":"27","author":"CS Venuto","year":"2012","unstructured":"Venuto CS, McGarry A, Ma Q, Kieburtz K. Pharmacologic approaches to the treatment of Huntington\u2019s disease. Mov Disord Off J Mov Disord Soc. 2012;27:31\u201341.","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"405_CR12","volume":"3","author":"T Mestre","year":"2009","unstructured":"Mestre T, Ferreira J, Coelho MM, Rosa M, Sampaio C. Therapeutic interventions for disease progression in Huntington\u2019s disease. Cochrane Database Syst Rev. 2009;3:CD006455.","journal-title":"Cochrane Database Syst Rev"},{"key":"405_CR13","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/nrneurol.2014.24","volume":"10","author":"CA Ross","year":"2014","unstructured":"Ross CA, Aylward EH, Wild EJ, Langbehn DR, Long JD, Warner JH, Scahill RI, Leavitt BR, Stout JC, Paulsen JS, Reilmann R, Unschuld PG, Wexler A, Margolis RL, Tabrizi SJ. Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat Rev Neurol. 2014;10:204\u201316.","journal-title":"Nat Rev Neurol"},{"key":"405_CR14","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1474-4422(10)70245-3","volume":"10","author":"CA Ross","year":"2011","unstructured":"Ross CA, Tabrizi SJ. Huntington\u2019s disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 2011;10:83\u201398.","journal-title":"Lancet Neurol"},{"key":"405_CR15","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.mam.2006.08.008","volume":"27","author":"B Ravikumar","year":"2006","unstructured":"Ravikumar B, Rubinsztein DC. Role of autophagy in the clearance of mutant huntingtin: a step towards therapy? Mol Aspects Med. 2006;27:520\u20137.","journal-title":"Mol Aspects Med"},{"key":"405_CR16","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0896-6273(01)00177-5","volume":"29","author":"MY Sherman","year":"2001","unstructured":"Sherman MY, Goldberg AL. Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases. Neuron. 2001;29:15\u201332.","journal-title":"Neuron"},{"key":"405_CR17","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.cell.2006.04.026","volume":"125","author":"RK Graham","year":"2006","unstructured":"Graham RK, Deng Y, Slow EJ, Haigh B, Bissada N, Lu G, Pearson J, Shehadeh J, Bertram L, Murphy Z, Warby SC, Doty CN, Roy S, Wellington CL, Leavitt BR, Raymond LA, Nicholson DW, Hayden MR. Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell. 2006;125:1179\u201391.","journal-title":"Cell"},{"key":"405_CR18","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1126\/science.1059581","volume":"293","author":"C Zuccato","year":"2001","unstructured":"Zuccato C, Ciammola A, Rigamonti D, Leavitt BR, Goffredo D, Conti L, MacDonald ME, Friedlander RM, Silani V, Hayden MR, Timmusk T, Sipione S, Cattaneo E. Loss of huntingtin-mediated BDNF gene transcription in Huntington\u2019s disease. Science. 2001;293:493\u20138.","journal-title":"Science"},{"key":"405_CR19","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1172\/JCI45691","volume":"121","author":"F Mochel","year":"2011","unstructured":"Mochel F, Haller RG. Energy deficit in Huntington disease: why it matters. J Clin Invest. 2011;121:493\u20139.","journal-title":"J Clin Invest"},{"key":"405_CR20","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.cmet.2006.10.004","volume":"4","author":"P Weydt","year":"2006","unstructured":"Weydt P, Pineda VV, Torrence AE, Libby RT, Satterfield TF, Lazarowski ER, Gilbert ML, Morton GJ, Bammler TK, Strand AD, Cui L, Beyer RP, Easley CN, Smith AC, Krainc D, Luquet S, Sweet IR, Schwartz MW, La Spada AR. Thermoregulatory and metabolic defects in Huntington\u2019s disease transgenic mice implicate PGC-1alpha in Huntington\u2019s disease neurodegeneration. Cell Metab. 2006;4:349\u201362.","journal-title":"Cell Metab"},{"key":"405_CR21","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.cell.2006.09.015","volume":"127","author":"L Cui","year":"2006","unstructured":"Cui L, Jeong H, Borovecki F, Parkhurst CN, Tanese N, Krainc D. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell. 2006;127:59\u201369.","journal-title":"Cell"},{"key":"405_CR22","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0896-6273(03)00594-4","volume":"40","author":"S Gunawardena","year":"2003","unstructured":"Gunawardena S, Her L-S, Brusch RG, Laymon RA, Niesman IR, Gordesky-Gold B, Sintasath L, Bonini NM, Goldstein LSB. Disruption of axonal transport by loss of huntingtin or expression of pathogenic polyQ proteins in Drosophila. Neuron. 2003;40:25\u201340.","journal-title":"Neuron"},{"key":"405_CR23","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1001\/archneur.62.1.46","volume":"62","author":"S Gunawardena","year":"2005","unstructured":"Gunawardena S, Goldstein LSB. Polyglutamine diseases and transport problems: deadly traffic jams on neuronal highways. Arch Neurol. 2005;62:46\u201351.","journal-title":"Arch Neurol"},{"key":"405_CR24","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/nrn1806","volume":"6","author":"E Cattaneo","year":"2005","unstructured":"Cattaneo E, Zuccato C, Tartari M. Normal huntingtin function: an alternative approach to Huntington\u2019s disease. Nat Rev Neurosci. 2005;6:919\u201330.","journal-title":"Nat Rev Neurosci"},{"key":"405_CR25","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0166-2236(00)01721-5","volume":"24","author":"E Cattaneo","year":"2001","unstructured":"Cattaneo E, Rigamonti D, Goffredo D, Zuccato C, Squitieri F, Sipione S. Loss of normal huntingtin function: new developments in Huntington\u2019s disease research. Trends Neurosci. 2001;24:182\u20138.","journal-title":"Trends Neurosci"},{"key":"405_CR26","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1038\/nn1988","volume":"10","author":"CS Lobsiger","year":"2007","unstructured":"Lobsiger CS, Cleveland DW. Glial cells as intrinsic components of non-cell-autonomous neurodegenerative disease. Nat Neurosci. 2007;10:1355\u201360.","journal-title":"Nat Neurosci"},{"key":"405_CR27","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/jnen\/60.2.161","volume":"60","author":"E Sapp","year":"2001","unstructured":"Sapp E, Kegel KB, Aronin N, Hashikawa T, Uchiyama Y, Tohyama K, Bhide PG, Vonsattel JP, DiFiglia M. Early and progressive accumulation of reactive microglia in the Huntington disease brain. J Neuropathol Exp Neurol. 2001;60:161\u201372.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"Pt 7","key":"405_CR28","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1093\/brain\/awm044","volume":"130","author":"YF Tai","year":"2007","unstructured":"Tai YF, Pavese N, Gerhard A, Tabrizi SJ, Barker RA, Brooks DJ, Piccini P. Microglial activation in presymptomatic Huntington\u2019s disease gene carriers. Brain J Neurol. 2007;130(Pt 7):1759\u201366.","journal-title":"Brain J Neurol"},{"key":"405_CR29","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/ng1542","volume":"37","author":"F Giorgini","year":"2005","unstructured":"Giorgini F, Guidetti P, Nguyen Q, Bennett SC, Muchowski PJ. A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease. Nat Genet. 2005;37:526\u201331.","journal-title":"Nat Genet"},{"key":"405_CR30","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1002\/mds.26007","volume":"29","author":"EJ Wild","year":"2014","unstructured":"Wild EJ, Tabrizi SJ. Targets for future clinical trials in Huntington\u2019s disease: what\u2019s in the pipeline? Mov Disord Off J Mov Disord Soc. 2014;29:1434\u201345.","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"405_CR31","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/ng864","volume":"30","author":"A Kazantsev","year":"2002","unstructured":"Kazantsev A, Walker HA, Slepko N, Bear JE, Preisinger E, Steffan JS, Zhu Y-Z, Gertler FB, Housman DE, Marsh JL, Thompson LM. A bivalent Huntingtin binding peptide suppresses polyglutamine aggregation and pathogenesis in Drosophila. Nat Genet. 2002;30:367\u201376.","journal-title":"Nat Genet"},{"key":"405_CR32","doi-asserted-by":"crossref","first-page":"10437","DOI":"10.1074\/jbc.275.14.10437","volume":"275","author":"Y Nagai","year":"2000","unstructured":"Nagai Y, Tucker T, Ren H, Kenan DJ, Henderson BS, Keene JD, Strittmatter WJ, Burke JR. Inhibition of polyglutamine protein aggregation and cell death by novel peptides identified by phage display screening. J Biol Chem. 2000;275:10437\u201342.","journal-title":"J Biol Chem"},{"key":"405_CR33","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1093\/hmg\/ddg144","volume":"12","author":"Y Nagai","year":"2003","unstructured":"Nagai Y, Fujikake N, Ohno K, Higashiyama H, Popiel HA, Rahadian J, Yamaguchi M, Strittmatter WJ, Burke JR, Toda T. Prevention of polyglutamine oligomerization and neurodegeneration by the peptide inhibitor QBP1 in Drosophila. Hum Mol Genet. 2003;12:1253\u20139.","journal-title":"Hum Mol Genet"},{"key":"405_CR34","doi-asserted-by":"crossref","first-page":"10444","DOI":"10.1016\/S0021-9258(17)34080-2","volume":"269","author":"D Derossi","year":"1994","unstructured":"Derossi D, Joliot AH, Chassaing G, Prochiantz A. The third helix of the Antennapedia homeodomain translocates through biological membranes. J Biol Chem. 1994;269:10444\u201350.","journal-title":"J Biol Chem"},{"key":"405_CR35","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/S0958-1669(02)00284-7","volume":"13","author":"JS Wadia","year":"2002","unstructured":"Wadia JS, Dowdy SF. Protein transduction technology. Curr Opin Biotechnol. 2002;13:52\u20136.","journal-title":"Curr Opin Biotechnol"},{"key":"405_CR36","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/nmeth0207-119","volume":"4","author":"A Prochiantz","year":"2007","unstructured":"Prochiantz A. For protein transduction, chemistry can win over biology. Nat Methods. 2007;4:119\u201320.","journal-title":"Nat Methods"},{"key":"405_CR37","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/nbt1201-1173","volume":"19","author":"MC Morris","year":"2001","unstructured":"Morris MC, Depollier J, Mery J, Heitz F, Divita G. A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat Biotechnol. 2001;19:1173\u20136.","journal-title":"Nat Biotechnol"},{"key":"405_CR38","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.addr.2011.12.014","volume":"64","author":"E-S Khafagy","year":"2012","unstructured":"Khafagy E-S, Morishita M. Oral biodrug delivery using cell-penetrating peptide. Adv Drug Deliv Rev. 2012;64:531\u20139.","journal-title":"Adv Drug Deliv Rev"},{"key":"405_CR39","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/sj.mt.6300045","volume":"15","author":"HA Popiel","year":"2007","unstructured":"Popiel HA, Nagai Y, Fujikake N, Toda T. Protein transduction domain-mediated delivery of QBP1 suppresses polyglutamine-induced neurodegeneration in vivo. Mol Ther J Am Soc Gene Ther. 2007;15:303\u20139.","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"405_CR40","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.neulet.2008.06.015","volume":"449","author":"HA Popiel","year":"2009","unstructured":"Popiel HA, Nagai Y, Fujikake N, Toda T. Delivery of the aggregate inhibitor peptide QBP1 into the mouse brain using PTDs and its therapeutic effect on polyglutamine disease mice. Neurosci Lett. 2009;449:87\u201392.","journal-title":"Neurosci Lett"},{"key":"405_CR41","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1093\/hmg\/ddv023","volume":"24","author":"I Aharony","year":"2015","unstructured":"Aharony I, Ehrnhoefer DE, Shruster A, Qiu X, Franciosi S, Hayden MR, Offen D. A Huntingtin-based peptide inhibitor of caspase-6 provides protection from mutant Huntingtin-induced motor and behavioral deficits. Hum Mol Genet. 2015;24:2604\u201314.","journal-title":"Hum Mol Genet"},{"key":"405_CR42","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/378403a0","volume":"378","author":"Y Trottier","year":"1995","unstructured":"Trottier Y, Lutz Y, Stevanin G, Imbert G, Devys D, Cancel G, Saudou F, Weber C, David G, Tora L. Polyglutamine expansion as a pathological epitope in Huntington\u2019s disease and four dominant cerebellar ataxias. Nature. 1995;378:403\u20136.","journal-title":"Nature"},{"key":"405_CR43","doi-asserted-by":"crossref","first-page":"6739","DOI":"10.1073\/pnas.110138997","volume":"97","author":"V Heiser","year":"2000","unstructured":"Heiser V, Scherzinger E, Boeddrich A, Nordhoff E, Lurz R, Schugardt N, Lehrach H, Wanker EE. Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: implications for Huntington\u2019s disease therapy. Proc Natl Acad Sci U S A. 2000;97:6739\u201344.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"405_CR44","doi-asserted-by":"crossref","first-page":"4764","DOI":"10.1073\/pnas.071058398","volume":"98","author":"JM Lecerf","year":"2001","unstructured":"Lecerf JM, Shirley TL, Zhu Q, Kazantsev A, Amersdorfer P, Housman DE, Messer A, Huston JS. Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington\u2019s disease. Proc Natl Acad Sci U S A. 2001;98:4764\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"405_CR45","doi-asserted-by":"crossref","first-page":"11563","DOI":"10.1073\/pnas.0505321102","volume":"102","author":"WJ Wolfgang","year":"2005","unstructured":"Wolfgang WJ, Miller TW, Webster JM, Huston JS, Thompson LM, Marsh JL, Messer A. Suppression of Huntington\u2019s disease pathology in Drosophila by human single-chain Fv antibodies. Proc Natl Acad Sci U S A. 2005;102:11563\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"405_CR46","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.molbrainres.2003.11.011","volume":"121","author":"RC Murphy","year":"2004","unstructured":"Murphy RC, Messer A. A single-chain Fv intrabody provides functional protection against the effects of mutant protein in an organotypic slice culture model of Huntington\u2019s disease. Brain Res Mol Brain Res. 2004;121:141\u20135.","journal-title":"Brain Res Mol Brain Res"},{"key":"405_CR47","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1097\/NEN.0b013e3181f530ec","volume":"69","author":"A Snyder-Keller","year":"2010","unstructured":"Snyder-Keller A, McLear JA, Hathorn T, Messer A. Early or late-stage anti-N-terminal Huntingtin intrabody gene therapy reduces pathological features in B6.HDR6\/1 mice. J Neuropathol Exp Neurol. 2010;69:1078\u201385.","journal-title":"J Neuropathol Exp Neurol"},{"key":"405_CR48","doi-asserted-by":"crossref","first-page":"17616","DOI":"10.1073\/pnas.0408134101","volume":"101","author":"DW Colby","year":"2004","unstructured":"Colby DW, Chu Y, Cassady JP, Duennwald M, Zazulak H, Webster JM, Messer A, Lindquist S, Ingram VM, Wittrup KD. Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular antibody. Proc Natl Acad Sci U S A. 2004;101:17616\u201321.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"405_CR49","doi-asserted-by":"crossref","first-page":"9013","DOI":"10.1523\/JNEUROSCI.2747-08.2008","volume":"28","author":"AL Southwell","year":"2008","unstructured":"Southwell AL, Khoshnan A, Dunn DE, Bugg CW, Lo DC, Patterson PH. Intrabodies binding the proline-rich domains of mutant huntingtin increase its turnover and reduce neurotoxicity. J Neurosci Off J Soc Neurosci. 2008;28:9013\u201320.","journal-title":"J Neurosci Off J Soc Neurosci"},{"key":"405_CR50","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1073\/pnas.022631799","volume":"99","author":"A Khoshnan","year":"2002","unstructured":"Khoshnan A, Ko J, Patterson PH. Effects of intracellular expression of anti-huntingtin antibodies of various specificities on mutant huntingtin aggregation and toxicity. Proc Natl Acad Sci U S A. 2002;99:1002\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"405_CR51","doi-asserted-by":"crossref","first-page":"13589","DOI":"10.1523\/JNEUROSCI.4286-09.2009","volume":"29","author":"AL Southwell","year":"2009","unstructured":"Southwell AL, Ko J, Patterson PH. Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington\u2019s disease. J Neurosci Off J Soc Neurosci. 2009;29:13589\u2013602.","journal-title":"J Neurosci Off J Soc Neurosci"},{"key":"405_CR52","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1083\/jcb.200710158","volume":"181","author":"C-E Wang","year":"2008","unstructured":"Wang C-E, Zhou H, McGuire JR, Cerullo V, Lee B, Li S-H, Li X-J. Suppression of neuropil aggregates and neurological symptoms by an intracellular antibody implicates the cytoplasmic toxicity of mutant huntingtin. J Cell Biol. 2008;181:803\u201316.","journal-title":"J Cell Biol"},{"key":"405_CR53","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1093\/hmg\/ddn139","volume":"17","author":"SC Warby","year":"2008","unstructured":"Warby SC, Doty CN, Graham RK, Carroll JB, Yang Y-Z, Singaraja RR, Overall CM, Hayden MR. Activated caspase-6 and caspase-6-cleaved fragments of huntingtin specifically colocalize in the nucleus. Hum Mol Genet. 2008;17:2390\u2013404.","journal-title":"Hum Mol Genet"},{"key":"405_CR54","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1093\/hmg\/ddn255","volume":"17","author":"B Mugat","year":"2008","unstructured":"Mugat B, Parmentier M-L, Bonneaud N, Chan HYE, Maschat F. Protective role of Engrailed in a Drosophila model of Huntington\u2019s disease. Hum Mol Genet. 2008;17:3601\u201316.","journal-title":"Hum Mol Genet"},{"key":"405_CR55","doi-asserted-by":"crossref","first-page":"e68775","DOI":"10.1371\/journal.pone.0068775","volume":"8","author":"Y Arribat","year":"2013","unstructured":"Arribat Y, Bonneaud N, Talmat-Amar Y, Layalle S, Parmentier M-L, Maschat F. A huntingtin peptide inhibits polyQ-huntingtin associated defects. PloS One. 2013;8:e68775.","journal-title":"PloS One"},{"key":"405_CR56","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/ng0896-442","volume":"13","author":"YP Goldberg","year":"1996","unstructured":"Goldberg YP, Nicholson DW, Rasper DM, Kalchman MA, Koide HB, Graham RK, Bromm M, Kazemi-Esfarjani P, Thornberry NA, Vaillancourt JP, Hayden MR. Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract. Nat Genet. 1996;13:442\u20139.","journal-title":"Nat Genet"},{"key":"405_CR57","doi-asserted-by":"crossref","first-page":"4842","DOI":"10.1523\/JNEUROSCI.22-12-04842.2002","volume":"22","author":"J Gafni","year":"2002","unstructured":"Gafni J, Ellerby LM. Calpain activation in Huntington\u2019s disease. J Neurosci Off J Soc Neurosci. 2002;22:4842\u20139.","journal-title":"J Neurosci Off J Soc Neurosci"},{"key":"405_CR58","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.15252\/embj.201490808","volume":"34","author":"M-T El-Daher","year":"2015","unstructured":"El-Daher M-T, Hangen E, Bruy\u00e8re J, Poizat G, Al-Ramahi I, Pardo R, Bourg N, Souquere S, Mayet C, Pierron G, L\u00e9v\u00eaque-Fort S, Botas J, Humbert S, Saudou F. Huntingtin proteolysis releases non-polyQ fragments that cause toxicity through dynamin 1 dysregulation. EMBO J. 2015;34:2255\u201371.","journal-title":"EMBO J"},{"key":"405_CR59","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jcis.2015.06.010","volume":"457","author":"A Mouri","year":"2015","unstructured":"Mouri A, Diat O, El Ghzaoui A, Ly I, Dorandeu C, Maurel JC, Devoisselle J-M, Legrand P. Development of pharmaceutical clear gel based on Peceol\u00ae, lecithin, ethanol and water: Physicochemical characterization and stability study. J Colloid Interface Sci. 2015;457:152\u201361.","journal-title":"J Colloid Interface Sci"},{"key":"405_CR60","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jcis.2013.10.058","volume":"416","author":"A Mouri","year":"2014","unstructured":"Mouri A, Diat O, El Ghzaoui A, Bauer C, Maurel JC, Devoisselle J-M, Dorandeu C, Legrand P. Phase behavior of reverse microemulsions based on Peceol(\u00ae). J Colloid Interface Sci. 2014;416:139\u201346.","journal-title":"J Colloid Interface Sci"},{"key":"405_CR61","first-page":"86","volume":"2","author":"Y Arribat","year":"2014","unstructured":"Arribat Y, Talmat-Amar Y, Paucard A, Lesport P, Bonneaud N, Bauer C, Bec N, Parmentier M-L, Benigno L, Larroque C, Maurel P, Maschat F. Systemic delivery of P42 peptide: a new weapon to fight Huntington\u00bfs disease. Acta Neuropathol Commun. 2014;2:86.","journal-title":"Acta Neuropathol Commun"},{"key":"405_CR62","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.nbd.2012.06.026","volume":"48","author":"MA Pouladi","year":"2012","unstructured":"Pouladi MA, Brillaud E, Xie Y, Conforti P, Graham RK, Ehrnhoefer DE, Franciosi S, Zhang W, Poucheret P, Compte E, Maurel J-C, Zuccato C, Cattaneo E, N\u00e9ri C, Hayden MR. NP03, a novel low-dose lithium formulation, is neuroprotective in the YAC128 mouse model of Huntington disease. Neurobiol Dis. 2012;48:282\u20139.","journal-title":"Neurobiol Dis"},{"key":"405_CR63","doi-asserted-by":"crossref","first-page":"e88797","DOI":"10.1371\/journal.pone.0088797","volume":"9","author":"S Lehmann","year":"2014","unstructured":"Lehmann S, Relano-Gines A, Resina S, Brillaud E, Casanova D, Vincent C, Hamela C, Poupeau S, Laffont M, Gabelle A, Delaby C, Belondrade M, Arnaud J-D, Alvarez M-T, Maurel J-C, Maurel P, Crozet C. Systemic delivery of siRNA down regulates brain prion protein and ameliorates neuropathology in prion disorder. PloS One. 2014;9:e88797.","journal-title":"PloS One"},{"key":"405_CR64","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1016\/S0140-6736(03)13304-1","volume":"361","author":"G Bates","year":"2003","unstructured":"Bates G. Huntingtin aggregation and toxicity in Huntington\u2019s disease. Lancet. 2003;361:1642\u20134.","journal-title":"Lancet"},{"key":"405_CR65","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1038\/ncb1477","volume":"8","author":"S Tam","year":"2006","unstructured":"Tam S, Geller R, Spiess C, Frydman J. The chaperonin TRiC controls polyglutamine aggregation and toxicity through subunit-specific interactions. Nat Cell Biol. 2006;8:1155\u201362.","journal-title":"Nat Cell Biol"},{"key":"405_CR66","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1038\/nsmb.1700","volume":"16","author":"S Tam","year":"2009","unstructured":"Tam S, Spiess C, Auyeung W, Joachimiak L, Chen B, Poirier MA, Frydman J. The chaperonin TRiC blocks a huntingtin sequence element that promotes the conformational switch to aggregation. Nat Struct Mol Biol. 2009;16:1279\u201385.","journal-title":"Nat Struct Mol Biol"},{"key":"405_CR67","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.jmb.2004.07.054","volume":"342","author":"DW Colby","year":"2004","unstructured":"Colby DW, Garg P, Holden T, Chao G, Webster JM, Messer A, Ingram VM, Wittrup KD. Development of a human light chain variable domain (V(L)) intracellular antibody specific for the amino terminus of huntingtin via yeast surface display. J Mol Biol. 2004;342:901\u201312.","journal-title":"J Mol Biol"},{"key":"405_CR68","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.cell.2004.06.018","volume":"118","author":"LR Gauthier","year":"2004","unstructured":"Gauthier LR, Charrin BC, Borrell-Pag\u00e8s M, Dompierre JP, Rangone H, Cordeli\u00e8res FP, De Mey J, MacDonald ME, Lessmann V, Humbert S, Saudou F. Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell. 2004;118:127\u201338.","journal-title":"Cell"},{"key":"405_CR69","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1089\/hum.2013.200","volume":"25","author":"LM Stanek","year":"2014","unstructured":"Stanek LM, Sardi SP, Mastis BM, Richards AR, Treleaven CM, Taksir TV, Misra K, Cheng SH, Shihabuddin LS. Silencing mutant huntingtin by AAV-mediated RNAi ameliorates disease manifestations in the YAC128 mouse model of Huntington\u2019s disease. Hum Gene Ther. 2014;25:461\u201374.","journal-title":"Hum Gene Ther"},{"key":"405_CR70","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.neuron.2012.05.009","volume":"74","author":"HB Kordasiewicz","year":"2012","unstructured":"Kordasiewicz HB, Stanek LM, Wancewicz EV, Mazur C, McAlonis MM, Pytel KA, Artates JW, Weiss A, Cheng SH, Shihabuddin LS, Hung G, Bennett CF, Cleveland DW. Sustained therapeutic reversal of Huntington\u2019s disease by transient repression of huntingtin synthesis. Neuron. 2012;74:1031\u201344.","journal-title":"Neuron"},{"key":"405_CR71","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1474-4422(13)70061-9","volume":"12","author":"TM Miller","year":"2013","unstructured":"Miller TM, Pestronk A, David W, Rothstein J, Simpson E, Appel SH, Andres PL, Mahoney K, Allred P, Alexander K, Ostrow LW, Schoenfeld D, Macklin EA, Norris DA, Manousakis G, Crisp M, Smith R, Bennett CF, Bishop KM, Cudkowicz ME. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol. 2013;12:435\u201342.","journal-title":"Lancet Neurol"},{"key":"405_CR72","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1172\/JCI80743","volume":"125","author":"EJ Wild","year":"2015","unstructured":"Wild EJ, Boggio R, Langbehn D, Robertson N, Haider S, Miller JRC, Zetterberg H, Leavitt BR, Kuhn R, Tabrizi SJ, Macdonald D, Weiss A. Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington\u2019s disease patients. J Clin Invest. 2015;125:1979\u201386.","journal-title":"J Clin Invest"},{"key":"405_CR73","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/mds.26331","volume":"30","author":"KM Shannon","year":"2015","unstructured":"Shannon KM, Fraint A. Therapeutic advances in Huntington\u2019s Disease. Mov Disord. 2015;30:1539\u201346.","journal-title":"Mov Disord"},{"key":"405_CR74","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.drudis.2013.05.011","volume":"18","author":"AA Kaspar","year":"2013","unstructured":"Kaspar AA, Reichert JM. Future directions for peptide therapeutics development. Drug Discov Today. 2013;18:807\u201317.","journal-title":"Drug Discov Today"},{"key":"405_CR75","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1186\/1471-2202-9-S3-S5","volume":"9 Suppl 3","author":"LR Hanson","year":"2008","unstructured":"Hanson LR, Frey WH. Intranasal delivery bypasses the blood\u2013brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci. 2008;9 Suppl 3:S5.","journal-title":"BMC Neurosci"},{"key":"405_CR76","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1152\/physrev.00041.2009","volume":"90","author":"C Zuccato","year":"2010","unstructured":"Zuccato C, Valenza M, Cattaneo E. Molecular mechanisms and potential therapeutical targets in Huntington\u2019s disease. Physiol Rev. 2010;90:905\u201381.","journal-title":"Physiol Rev"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-016-0405-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T16:09:56Z","timestamp":1655309396000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.ojrd.com\/content\/11\/1\/24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,17]]},"references-count":76,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["405"],"URL":"https:\/\/doi.org\/10.1186\/s13023-016-0405-3","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,17]]},"article-number":"24"}}